Catalase activity in Candida albicans exposed to antineoplastic drugs

References

1. Abrahamsen T. G., Widing E., Glomstein A., Gaustad P. 1992; Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis 24:391–393 [CrossRef]
   [Google Scholar]
2. Aebi H. 1984; Catalase in vitro . Method Enzymol 105:121–126
   [Google Scholar]
3. Ahearn D. G., McGlohn M. S. 1984; In vitro susceptibilities of sucrose-negative Candida tropicalis , Candida lusitaniae , and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole and ketoconazole. J Clin Microbiol 19:412–416
   [Google Scholar]
4. Batey M. A., Wright J. G., Azzabi A., Newell D. R., Lind M. J., Calvert A. H., Boddy A. V. 2002; Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Eur J Cancer 38:1081–1089 [CrossRef]
   [Google Scholar]
5. Bradford M. M. 1976; A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254 [CrossRef]
   [Google Scholar]
6. Brajtburg J., Elberg S., Kobayashi G. S., Medoff G. 1988; Interference with effects of amphotericin B on Candida albicans cells by 2-chloroethyl-1-nitrosoureas. Antimicrob Agents Chemother 32:327–330 [CrossRef]
   [Google Scholar]
7. Conly J., Rennie R., Johson J., Farah S., Hellman L. 1992; Disseminated candidiasis due to amphotericin B-resistant Candida albicans . J Infect Dis 165:761–764 [CrossRef]
   [Google Scholar]
8. Davies A., Brailsford S., Broadley K., Beighton D. 2002; Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med 16:527–531 [CrossRef]
   [Google Scholar]
9. Dick J. D., Merz W. G., Saral R. 1980; Incidence of polyene resistant yeast recovered from clinical specimens. Antimicrob Agents Chemother 18:158–163 [CrossRef]
   [Google Scholar]
10. Egorin M. J., Forrest A., Belani C. P., Ratain M. J., Abrams J. S., Van Echo D. A. 1989; A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49:3129–3133
    [Google Scholar]
11. Ghannoum M. A. 1986; Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata . Mycopathologia 95:175–181 [CrossRef]
    [Google Scholar]
12. Lineweaver H., Burk D. 1934; The determination of enzyme dissociation constant. J Am Chem Soc 116:688
    [Google Scholar]
13. Kerridge D., Nicholas R. D. 1986; Drug resistance in the opportunistic pathogens Candida albicans and C. glabrata . J Antimicrob Chemother 18:39–49
    [Google Scholar]
14. Liliemark J., Peterson C. 1991; Pharmacokinetic optimization of anticancer therapy. Clin Pharmacokinet 21:213–231 [CrossRef]
    [Google Scholar]
15. Morikawa N., Mori T., Abe T., Ghoda M., Takeyama M., Hori S. 1997; Pharmacokinetics of methotrexate in plasma and cerebrospinal fluid. Ann Pharmacother 31:1153–1156
    [Google Scholar]
16. Nakagawa Y., Kanbe T., Mizuguchi I. 2003; Disruption of the human pathogenic yeast Candida albicans catalase gene decreased survival in mouse-model infection and elevated susceptibility to higher temperature and to detergents. Microbiol Immunol 47:395–403 [CrossRef]
    [Google Scholar]
17. Nolte F. S., Parkinson T., Falconer D. J., Dix S., Williams J., Gilmore C., Geller R., Wingard J. R. 1997; Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 44:196–199
    [Google Scholar]
18. Salonen J. H., Richardson M. D., Gallacher K., Issakainen J., Helenius H., Lehtonen O. P., Nikoskelainen J. 2000; Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae . J Hosp Infect 45:293–301 [CrossRef]
    [Google Scholar]
19. Sarachek A., Henderson L. A. 1991; Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents. Mycoses 34:177–182
    [Google Scholar]
20. Sokol-Anderson M., Brajtburg J., Medoff G. 1986; Amphotericin B induced oxidative damage and killing of Candida albicans . J Infect Dis 154:76–83 [CrossRef]
    [Google Scholar]
21. Sokol-Anderson M., Sligh J. E., Elberg S., Brajtburg J., Kobayashi G. S., Medoff G. 1988; Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 32:702–705 [CrossRef]
    [Google Scholar]
22. Vanden Bossche H., Marichal P., Odds C. F. 1994; Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2:393–400 [CrossRef]
    [Google Scholar]